Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Impressive presentationand off the website
https://cirata.com/investors/reports-and-presentations
A short but must listen and view
https://stream.brrmedia.co.uk/broadcast/6593dd56b012a6d30b474354/659cf80bd318bb466ee15f76
Stephen Kelly, Chief Executive Officer, commented:
"FY2023 has been an eventful year for all Cirata stakeholders, a near collapse of the business followed by a herculean effort to rebuild from the ground up. The March 9 announcement represented an existential crisis. Against all odds, the turnaround is well underway. Our Q3 and our Q4 reflect the first steps of a company coming back 'off the canvas'. Sequential growth in bookings through Q2, Q3, Q4 and transacting with companies such as GM, NatWest and Experian amplify the progress this company has made since the dark days after March 9. We completed the FY23 Turnaround Plan and now shift gears into the FY24 Growth Plan. We are getting into our stride, but this is minimum table stakes - we need to drive a much higher quality execution in our Go-to-Market model. The new structure of our sales organization with the leadership of Rich, Chris and Justin reflects a flatter, sharper, more customer focused Cirata. My personal thanks go to my colleagues and shareholders for their trust, diligence, and patience as we set the stage for growth in FY24. I am excited for the year that lies ahead."
Cirata's closing cash balance at 31 December 2023 is $18.2m compared to a guidance of $16.0m - $16.5m. This is due to good cash collections and strong cost management during the period. Cirata is targeting cash flow breakeven as we exit FY 2024.
Trading Update
Trading in line with management expectations
YE Cash balance exceeds expectations.
Https://www.voxmarkets.co.uk/rns/announcement/460b0464-cfc2-4480-b81a-28d9f4e8fffe/
Good luck to those who deserve it
74.8p UT
Continues to creep up finishing tonight at 74.2p UT
Keep it up, boys and girls
Nice to get a small top up at these prices (1.04p paid) to lower my average
Nice to see the movement back north even on a low trading volume day
Only 114m shares and many tied up
Pivot Point 3rd Level Resistance 79.2p
Pivot Point 2nd Level Resistance 74.6p
High 73.0p High today
52-Week High 71.6p
13-Week High 71.6p
Pivot Point 1st Resistance Point 71.4p
Low today 69.0p
Previous Close 68.2p
With the Month high and 52 week high looming at 71.6p it only needs a push to go above.
Strong Company news could be the igniter.
EoY accounts due shortly after the New Year.
Hoping contract news will appear, as well.
Merry Xmas and a Happy New Year.
Transformative 2024 to come and back up the ladder.
Dont forget these !!!
As Cirata enters the period of closure of this quarter and the End of Year Accounts and next Trading update I will remind us of parts of the October 18th RNS .....
· H2 2023 bookings are expected to be in the range of $4.3m to $6.0m.
· Relative to prior periods this would represent:
o Sequential progression on H1 2023, with 54% bookings growth at the low end and 114% at the high end
o 5% bookings growth relative to H2 2022 at the low end and 46% growth at the high end
o FY 2023 bookings performance in the range of $7.1m to $8.8m
· Forecast closing cash position as of 31 December 2023 of $16.0m to $16.5m
The pipeline has been appropriately cleansed and qualified, and management is confident that what remains is robust and of high quality. The Q4 activity started well as evidenced by the already announced contract expansion with NatWest and a material renewal from US insurer HCSC, with a combined total of $1.3m in bookings. The Q3 bookings reported plus the early Q4 bookings activity announced result in H2 bookings total to date of $3.0m.
Overall, Cirata's pipeline continues to be in the early stages of a rebuild and we are entirely focused on building a strong basis for growth in 2024 in line with the Company's Turnaround Plan. We continue to target cashflow break even as we exit 2024 and move into 2025.
Approach to Disclosure of New Contracts
During FY23, Cirata has communicated news of new contracts and renewals to investors which included smaller contracts to disclose the ongoing progress being made in re-engaging with current and prospective customers and the positioning of Cirata for growth and success.
Going forward intra-quarter, the Company will adopt a policy of only announcing material customer wins and renewals.
Summary data on all deals will be captured within quarterly trading updates.
As we enter an exciting period I assume that everything is in order for an early Jan 2024 report. ....ONLY 3-4 weeks at the latest
I am sure the Stephen Kelly and the BOD are on with this NOW, with the Xmas Break upon us.
I can see minimum 100p before the EOY RNS, such is the confidence
9am Meeting
RNS x1 to follow
RNS x2 ?
We shall see soon enough
Two or more shareholders who attend the adjourned meeting in person or by proxy will constitute a quorum, regardless of the number ordinary shares they hold or represent.
The adjourned general meeting will therefore be held at 3rd Floor Beit Golan, 1 Golan St. Corner HaNegev, Airport City 7019900, Israel at 11:00 a.m. IST (09:00 a.m. GMT) on 14 December 2023 (the "Adjourned Meeting"). Valid proxy votes submitted in respect of the General Meeting will be counted at the Adjourned Meeting. Based on the proxy votes and forms of direction received for the General Meeting, had the meeting been quorate, the resolutions would have been passed.
600 000 options awarded at 57p between 4 people, each getting 150 000 options
Oct 18th RNS Trading update ....
The outlook for H2 bookings' performance remains unchanged.
· H2 2023 bookings are expected to be in the range of $4.3m to $6.0m.
· Relative to prior periods this would represent:
o Sequential progression on H1 2023, with 54% bookings growth at the low end and 114% at the high end
o 5% bookings growth relative to H2 2022 at the low end and 46% growth at the high end
o FY 2023 bookings performance in the range of $7.1m to $8.8m
· Forecast closing cash position as of 31 December 2023 of $16.0m to $16.5m
The pipeline has been appropriately cleansed and qualified, and management is confident that what remains is robust and of high quality. The Q4 activity started well as evidenced by the already announced contract expansion with NatWest and a material renewal from US insurer HCSC, with a combined total of $1.3m in bookings. The Q3 bookings reported plus the early Q4 bookings activity announced result in H2 bookings total to date of $3.0m.
Overall, Cirata's pipeline continues to be in the early stages of a rebuild and we are entirely focused on building a strong basis for growth in 2024 in line with the Company's Turnaround Plan. We continue to target cashflow break even as we exit 2024 and move into 2025.
Approach to Disclosure of New Contracts
During FY23, Cirata has communicated news of new contracts and renewals to investors which included smaller contracts to disclose the ongoing progress being made in re-engaging with current and prospective customers and the positioning of Cirata for growth and success.
Going forward intra-quarter, the Company will adopt a policy of only announcing material customer wins and renewals.
Summary data on all deals will be captured within quarterly trading updates.
Stephen Kelly, Chief Executive Officer, commented.
"Our turnaround plan is developing momentum, and our collective focus now is squarely on growth and tracking towards cash-flow breakeven. We are pleased with the level of engagement with both our partners and customers. It has been a period of "root and branch" positive changes with a new Board, new Management Team and new Company name and brand. These are early days in the Company's transition and although we can see the green shoots of progress as evidenced by recent contract announcements, we realize that our future success relies on a continued relentless focus on growth and execution."
See 05 47 this morning
If the merger goes ahead Chuditch could be key farm in or acquisition
BUT
let's see what happens between them first.
On the same wavelength Legin